

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(10) **DK/EP 1984012 T3**

(12) **Oversættelse af
europæisk patentskrift**

-
- (51) Int.Cl.: **A 61 K 38/11 (2006.01)** **A 61 P 9/00 (2006.01)** **A 61 P 9/02 (2006.01)**
A 61 P 9/04 (2006.01) **A 61 P 9/12 (2006.01)** **C 07 K 7/16 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2016-03-29**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2015-12-30**
- (86) Europæisk ansøgning nr.: **07804708.1**
- (86) Europæisk indleveringsdag: **2007-02-12**
- (87) Den europæiske ansøgnings publiceringsdag: **2008-10-29**
- (86) International ansøgning nr.: **IB2007002248**
- (87) Internationalt publikationsnr.: **WO2007144768**
- (30) Prioritet: **2006-02-13 US 772528 P**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR**
- (73) Patenthaver: **Ferring B.V., Polaris Avenue , 144, 2132 JX Hoofddorp, Holland**
- (72) Opfinder: **LAPORTE, Regent, 11344 Trillum Way, San Diego, CA 92131, USA**
RIVIÈRE, Pierre, J.-M., 3993 Via Cangrejo, San Diego, CA 91230, USA
- (74) Fuldmægtig i Danmark: **Awapatent A/S, Rigensgade 11, 1316 København K, Danmark**
- (54) Benævnelse: **ANVENDELSE AF PEPTIDISK VASOPRESSIN-RECEPTOR-AGONISTER**
- (56) Fremdragne publikationer:
WO-A-99/46283
WO-A-2006/020491
GB-A- 1 076 984
US-A- 4 829 051
US-A1- 2004 229 798
DATABASE WPI Week 200376 Derwent Publications Ltd., London, GB; AN 2003-812511 XP002464026 -& WO 03/082334 A (WAKAMOTO PHARM CO LTD) 9 October 2003 (2003-10-09)
WALTER E.: "Therapie des hepatorenen Syndroms" PRAXIS, SCHWEIZERISCHE RUNDSCHAU FÜR MEDIZIN-INHALT & ZUSAMMENFASSUNGEN, [Online] vol. 86, no. 4, 1997, XP002464024 ISSN: 1661-8157 Retrieved from the Internet: URL: http://www.praxis.ch/content/1997/04_1_997.html [retrieved on 2008-01-10]
DÖHLER K D ET AL: "Wirkmechanismen der vasokonstriktiven Therapie der Ösophagusvarizenblutung" ZEITSCHRIFT FÜR GASTROENTEROLOGIE, vol. 41, 2003, pages 1001-1016, XP002464025
REID I A: "Role of vasopressin deficiency in the vasodilation of septic shock", CIRCULATION, LIPPINCOTT WILLIAMS & WILKINS, US, vol. 95, no. 5, 4 March 1997 (1997-03-04), pages 1108-1110, XP002312037, ISSN: 0009-7322

DESCRIPTION

Field of the Invention

[0001] The present invention relates to the use of novel compounds for the manufacture of a medicament for treatment of *inter alia* conditions associated with critical care as well as to a method for treatment of said conditions, wherein said compounds are administered.

Background

[0002] Peptidic vasopressin V1a receptor agonists, such as terlipressin, have recently (see e.g. O'Brian et al., Lancet 359 (9313):1209-10, June 4th, 2002) received increased attention for clinical use in treatment of critical care diseases and conditions, including shock of hypovolemic (e.g. hemorrhagic) or vasodilatory (e.g. septic) origin, bleeding esophageal varices (BEV), hepatorenal syndrome (HRS), cardiopulmonary resuscitation and anesthesia-induced hypotension. They have also been shown to have clinical use in the treatment of orthostatic hypotension, paracentesis-induced circulatory dysfunction, intra-operative blood loss and blood loss associated with burn débridement and epistaxis.

[0003] In treating critical care conditions it is highly desirable to control the arterial blood pressure, and the drug used is typically administered intravenously. Continuous intravenous drug infusion at increasing or decreasing rates is a practical means of providing the desired degree of control. The attainment of so-called "steady state" plasma concentrations of drug depends on the elimination half life of the drug infused. It is generally recognised that steady state plasma concentration is achieved after a period of time equivalent to three times the elimination half life of the drug. To be practical in a clinical setting the desired arterial blood pressure at the steady state should be attained in about two hours, preferably in one hour or less. V1a agonists with an elimination half life longer than 1 hour are therefore usually not considered useful for critical care treatment.

[0004] A disadvantage of terlipressin in many critical care situations is its long duration of action, which makes it difficult to titrate its effect as the disease state changes. Terlipressin metabolites have agonist activity at the human V1a (hV1a) receptor.





[0005] Also the compound known as F180 (cf. example 3 in US patent No. 5,459,236) has an inconveniently long duration of action to be considered for the treatment of most critical care conditions.


[0006] Non-specific receptor agonist activity is the main disadvantage of other existing compounds, e.g. [Phe²,Orn⁸]OT (cf. example 1f in US patent No. 3,352,843) and arginine-vasopressin (AVP). Activity at related receptors such as V1b, V2 and oxytocin (OT) receptors may potentially generate undesirable side effects and safety concerns. As an example, V2 receptor activation may induce antidiuresis (cf. desmopressin), release of coagulation/thrombolysis factors, and induce vasodilation/hypotension with reflex tachycardia. The latter side effect may also be induced by OT receptor agonist activity.

[0007] It is an objective of the present invention to provide use of compounds especially in the treatment of conditions associated with critical care, as well as providing further uses of said compounds.



Disclosure of the Invention

[0008] The present invention relates to a compound selected from a group consisting of:










and





for use in the treatment of hypertensive gastropathy bleeding, sepsis, severe sepsis, septic shock, prolonged and severe hypotension, intradialytic hypotension, cardiac arrest, trauma related blood loss, vasodilatory shock induced by cardio-pulmonary bypass, milrinone-induced vasodilatory shock in congestive heart failure, hepatorenal syndrome type I, anaphylactic shock, cardiovascular instability induced by brain death, for the treatment of hypotension in severe sepsis, acute respiratory distress syndrome or acute lung injury, or for the treatment of inadequate tissue oxygenation, shock induced by metformin intoxication, mitochondrial disease or cyanide poisoning, vascular leak syndrome induced by interleukin-2 or other cytokines, denileukin difitox or other immunotoxins, or ovarian hyperstimulation syndrome, hypertension induced by end-stage renal disease, severe burns, thermal injury, reperfusion injury, ascites, vasodepressor syncope, including vasovagal syncope, postural hypotension with syncope or neurocardiogenic syncope, toxic shock syndrome or idiopathic systemic capillary leak syndrome (Clarkson's disease).

[0009] The present invention also relates to compound selected from a group consisting of:



and



for use in the manufacture of a medicament for treatment of hypertensive gastropathy bleeding, sepsis, severe sepsis, septic shock, prolonged and severe hypotension, intradialytic hypotension, cardiac arrest, trauma related blood loss, vasodilatory shock induced by cardio-pulmonary bypass, milrinone-induced vasodilatory shock in congestive heart failure, hepatorenal syndrome type I, anaphylactic shock, cardiovascular instability induced by brain death, for use in the manufacture of a medicament for treatment of hypotension in severe sepsis, acute respiratory distress syndrome or acute lung injury, or for use in the manufacture of a medicament for treatment of inadequate tissue oxygenation, shock induced by metformin intoxication, mitochondrial disease or cyanide poisoning, vascular leak syndrome induced by interleukin-2 or other cytokines, denileukin difitox or other immunotoxins, or ovarian hyperstimulation syndrome, hypertension induced by end-stage renal disease, severe burns, thermal injury, reperfusion injury, ascites, vasodepressor syncope, including vasovagal syncope, postural hypotension with syncope or neurocardiogenic syncope, toxic shock syndrome or idiopathic systemic capillary leak syndrome (Clarkson's disease).

[0010] For more detail on the above indications and conditions see e.g. the references Bruha, R. et al. Hepatogastroenterology 49:1161-1166, 2002; Landry, D.W. et al. Circulation 95:1122-1125, 1997; Argenziano, M. et al. Circulation 96:II-286-II-290, 1997; Landry, D.W. et al. U.S. patent application published as no. 2004-229798; Wenzel, V. et al. N. Engl. J. Med. 350:105-113, 2004; Okin, C.R. et al. Obstet. Gynecol. 97:867-872, 2001; Gold, J. et al. Am. J. Cardiol. 85:506-508, 2000; Sharma, R.M. and Settler, R. Anest. Analg. 101:833-834, 2005; Solanik, P. et al. J. Gastroenterol. Hepatol. 18:152-156, 2000; Yoshioka, T. et al. Neurosurgery 18:565-567, 1986; Kill, C. et al. Int. Arch. Allergy Immunol. 134:260-261, 2004; Westphal, M. et al. Annual Congress of the Society of Critical Care Medicine, Abstract no. 196470, 2006; Landry, D.W. and Oliver, J.A. N. Engl. J. Med. 345(8):588-595, 2001; Baluna, R. and Vitetta, E.S. Immunopharm. 37:117-132, 1997; Delbaere, A. et al. Endocrine. 26:285-290, 2005; Agarwal, R. Cardiol. Clin. 23:237-248, 2005; Demling, R.H. J. Burn Care Rehabil. 26:207-227, 2005; Bonder, C.S. and Kubes, P. Am. J. Physiol. 284:729-733, 2003; Seal, J.B. and Gewertz, B.L. Ann. Vasc. Surg. 19:572-584, 2005; Zaban, P., Cerny, M. Physiol. Res. 52:507-516, 2003; Bermejo, J.F. and Munoz-Fernandez, M.A. Viral Immunol. 17:535-544, 2004; Arroyo, V. Ann. Hepatol. 1:72-79,

2002; Hainsworth, R. Clin. Auton. Res. 14 Suppl 1:18-24, 2004; Chuang, Y.Y. et al. Paediatr. Drugs. 7:11-25, 2005 ; Cau, C. Minerva Med. 90:391-396, 1999.

[0011] For the purposes of the present invention, the following terminology is used.

[0012] Aromatic carbocyclic ring systems includes phenyl and naphthyl.

[0013] A five-membered heteroaromatic ring system is a monocyclic aromatic ring system having five ring atoms, wherein 1, 2 or 3 ring atoms are independently selected from N, O and S. Preferred such ring systems are selected from a group consisting of thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl and tetrazolyl.

[0014] A six-membered heteroaromatic ring system is a monocyclic aromatic ring system having six ring atoms, wherein 1, 2 or 3 ring atoms are independently selected from N, O and S. It is preferably selected from a group consisting of pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

[0015] A bicyclic heteroaromatic ring system is a ring system having two five- or six-membered heteroaromatic rings, or a phenyl and a five- or six-membered heteroaromatic ring, or a phenyl and a heterocyclyl ring, or a five- or six-membered heteroaromatic ring and a heterocyclyl ring; connected by a ring fusion, said bicyclic heteroaromatic ring system comprising 8 to 12 ring atoms, wherein 1, 2 or 3 of the ring atoms are independently selected from N, O and S. It is preferably selected from a group consisting of indole, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzo-dioxan, coumarin, benzofuran, 1,2-benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, pyrrolizidine and quinolizidine.







[0016] A heterocyclyl or heterocyclic moiety is a saturated or partially saturated ring system having 3 to 7 ring atoms, wherein 1, 2 or 3 ring atoms are independently selected from N, O and S. Heterocyclyl moieties are preferably selected from a group consisting of aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine, pyrazolidine, di-oxolane, tetrahydrofuran, piperidine, piperazine, morpholine, tetrahydropyran, 1,4-dioxanyl, homopiperidinyl, homopiperazinyl and hexamethylene oxide.


[0017] It deserves mentioning that e.g. also isopropyl and 2-n-butyl groups are encompassed by the expression C₁₋₆ straight chain alkyl, as said expression is not related to the binding site of the straight chain in question.

[0018] C₁₋₆ denotes having from one to six carbon atoms, including any number therebetween, and this nomenclature is used analogously herein.

[0019] Examples of pharmaceutically acceptable salts comprise acid addition salts, e.g. a salt formed by reaction with hydrohalogen acids, such as hydrochloric acid, and mineral acids, such as sulphuric acid, phosphoric acid and nitric acid, as well as aliphatic, alicyclic, aromatic or heterocyclic sulphonic or carboxylic acids, such as formic acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybenzoic acid, embonic acid, methanesulphonic acid, ethanesulphonic acid, hydroxyethanesulphonic acid, halobenzenesulphonic acid, toluenesulphonic acid and naphthalenesulphonic acid.

[0020] The compound of the invention is selected from a group consisting of:





(7)

[0021] The number in parenthesis denotes the compound as referred to in the following.

[0022] The pharmaceutical composition used when practising the present invention may be adapted for oral, intravenous, topical, intraperitoneal, nasal, buccal, sublingual or subcutaneous administration or for administration via the respiratory tract *e.g.* in the form of an aerosol or an air-suspended fine powder. The composition may thus for instance be in the form of tablets, capsules, powders, microparticles, granules, syrups, suspensions, solutions, transdermal patches or suppositories.

[0023] The pharmaceutical composition used may optionally comprise *e.g.* at least one further additive selected from a disintegrating agent, binder, lubricant, flavoring agent, preservative, colorant and any mixture thereof. Examples of such and other additives are found in "Handbook of Pharmaceutical Excipients"; Ed. A.H. Kibbe, 3rd Ed., American Pharmaceutical Association, USA and Pharmaceutical Press UK, 2000.

[0024] The pharmaceutical composition used is most preferably adapted for parenteral administration. It may comprise a sterile aqueous preparation of the compounds of the invention preferably isotonic with the blood of the recipient. This aqueous preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The injectable aqueous formulation Remestyp® (terlipressin) is exemplary of a suitable pharmaceutical formulation type. The preparation may also be a sterile injectable solution or suspension in a diluent or solvent, for example as a solution in 1,3-butane diol. Water, Ringer's solution, and isotonic sodium chloride solution are exemplary acceptable diluents. Sterile, fixed oils may be employed as a solvent or suspending medium. Bland fixed oils, including synthetic mono or di-glycerides, and fatty acids, such as oleic acid, may also be used.

[0025] The typical dosage of the compounds used according to the present invention varies within a wide range and will depend on various factors such as the individual needs of each patient and the route of administration. The dosage administered by infusion is generally within the range of 0.01-200 µg/kg body weight per hour. A physician of ordinary skill in the art will be able to optimise the dosage to the situation at hand.

[0026] The abbreviations used are:

Abu	2-aminobutyric acid
Boc	<i>tert</i> -butoxycarbonyl
BOP	benzotriazol-1-yloxy trisdimethylamino-phosphonium hexafluorophosphate
Dbu	2,4-diaminobutyric acid
DCC	<i>N,N'</i> -dicyclohexylcarbodiimide
DCHA	dicyclohexylamine
DCM	dichloromethane
DIAD	diisopropyl diazodicarboxylate
DIC	<i>N,N'</i> -diisopropylcarbodiimide
DIEA	<i>N,N</i> -diisopropyl- <i>N</i> -ethylamine
DMF	<i>N,N</i> -dimethylformamide
Fm	9-fluorenylmethyl
Fmoc	

	9-fluorenylmethoxycarbonyl
Hgn	homoglutamine
Hmp	2-hydroxy-3-mercaptopropionic acid
HOBt	1-hydroxybenzotriazole
HPLC	high performance liquid chromatography
<i>i</i>	iso
Mmt	4-methoxytrityl
Mob	<i>p</i> -methoxybenzyl
MS	mass spectrometry
Orn	ornithine
Ph	phenyl
Pr	propyl
PyBOP	benzotriazol-1-yloxy trispyrrolidine-phosphonium hexafluorophosphate
<i>o</i> -NBS-Cl	2-nitrobenzenesulfonyl chloride
OT	oxytocin
Rt	retention time
TFA	trifluoroacetic acid
TIS	triisopropylsilane
TMOF	trimethylorthoformate
TPP	triphenylphosphine
Trt	trityl
VT	vasotocin, [Ile ³]vasopressin

[0027] Unless otherwise specified L-amino acids were used, and conventional amino acid terminology is adhered to.

Experimental (synthesis)

[0028] Amino acid derivatives and resins were purchased from commercial providers (Novabiochem, Bachem Peptide International and PepTech Corporation). Fmoc-Hgn-OH was synthesised according to literature (Wisniewski, K., Kolodziejczyk, A.S. Org. Prep. Proced. Int. 1997, 29, 338-341). Other chemicals and solvents were provided from Sigma-Aldrich, Fisher Scientific and VWR.

[0029] The compounds herein were synthesised by standard methods in solid phase peptide chemistry utilising both Fmoc and

Boc methodology. Unless otherwise provided, all reactions were performed at room temperature. In addition to the references cited *supra*, the following standard reference literature provides further guidance on general experimental set up, as well as on the availability of required starting material and reagents:

Kates, S.A., Albericio, F., Eds., *Solid Phase Synthesis. A Practical Guide*, Marcel Dekker, New York, Basel, 2000;

Stewart, J.M., Young, J.D. *Solid Phase Synthesis*, Pierce Chemical Company, 1984;

Bisello, et al., *J. Biol. Chem.* 1998, 273, 22498-22505; and

Merrifield, J. *Am. Chem. Soc.* 1963, 85, 2149-2154.

[0030] Purity of the synthesized peptide may be determined by analytical reversed phase HPLC. Structural integrity of the peptides may be confirmed using amino acid analysis and electrospray mass spectrometry.

[0031] The peptides synthesised by Fmoc methodology were cleaved with a TFA/TIS/H₂O 96/2/2 (v/v/v) solution, and cleavage in Boc methodology was accomplished with 90% HF/10% anisole (v/v) solution. Disulfide bridge (ring) formation was achieved by oxidation of linear peptides dissolved in 10% TFA (aq) with iodine. Peptides were purified by preparative HPLC in triethylammonium phosphate buffers (aq). The compounds were finally converted to acetate salts using conventional HPLC methodology. The fractions with a purity exceeding 97% were pooled and lyophilised.

Synthesis of peptides with alkylated side chain in position no. 8:

[0032] The peptides were assembled with Fmoc methodology. The diamino acid residue in position no. 8 was introduced with an acid labile (*i.e.* removable with a solution containing 1-2% TFA) protecting group, such as methoxytrityl (Mmt; see Barlos, K. et al. in *Peptides 1992*, Schneider, C.H., Eberle, A.N., Eds., ESCOM Science Publishers B.V., 1993, pp 283-284). Resin bound peptide was treated with a DCM/TIS/TFA 93/5/2 (v/v/v) solution for the Mmt group removal. Reductive alkylation with acetone/NaBH(OAc)₃ provided the *N*-isopropyl peptide.

[0033] To avoid undesirable *N,N*-dialkylation in reductive alkylation in the above procedure, which may occur when straight chain alkyl aldehydes are used, an alternative was developed, wherein after the Mmt removal the amino group was first derivatised with 2-nitrobenzenesulfonyl chloride (*o*-NBS-Cl; see Fukuyama, T.; Jow, C.-K.; Cheung, M. *Tetrahedron Lett.* 1995, 36, 6373-6374). The resulting sulphonamide was then alkylated with an appropriate alcohol under conventional Mitsunobu reaction conditions, typically utilising TPP/DIAD in 1,2-dimethoxyethane (Mitsunobu, O. *Synthesis* 1981, 1-28). The *o*-NBS-Cl group was subsequently removed with 5% potassium thiophenolate in DMF, after which the peptide was cleaved from the resin.

Synthesis of peptides with *N*-alkylated side chain in position no. 4:

[0034] The peptides were assembled with Boc methodology. The residue in position no. 4 was introduced in the sequence as Boc-Asp(OFm)-OH. After complete peptide assembly the side chain protection was removed with 30% piperidine in DMF. The resulting free carboxylic group was converted to the desired amide by coupling with an appropriate amine mediated by PyBOP or BOP/DIEA. The *N*-terminal Boc group was then removed, followed by HF cleavage, cyclisation and purification by HPLC.

[0035] Table 1 lists the compounds prepared by the above procedure. R₁ is H for all compounds except no. 7, where R₁ is CH₃. An asterisk "*" marks compounds of the invention.

Table 1. Compounds prepared with the formula (I)

Ar	Substituent					Denoted
	m	n	R ₂	p	R ₃	
Ph	2	0	H	2	H	8
Ph	3	0	H	3	H	9
Ph	2	0	OCH ₃	3	H	10
Ph	3	0	H	2	H	11

Ar	Substituent					Denoted
	m	n	R ₂	p	R ₃	
4-pyridyl	2	0	H	2	H	12
4-thiazolyl	2	0	H	2	H	13
2-thienyl	2	0	H	2	H	14
3-thienyl	2	0	H	2	H	15
Ph	2	0	OH	3	H	16
2-pyridyl	2	0	H	2	H	17
3-pyridyl	2	0	H	2	H	18
Ph	2	0	CH ₃	3	H	19
Ph	2	1	CH ₃	3	H	20
Ph	2	1	CH(CH ₃) ₂	3	H	21
Ph	3	0	H	3	CH(CH ₃) ₂	1*
Ph	3	0	H	2	CH(CH ₃) ₂	22
Ph	1	2	OH	3	H	23
Ph	1	0	OH	3	H	24
2-furyl	2	0	H	3	H	25
Ph	1	3	OH	3	H	2*
2-furyl	2	0	H	2	H	26
Ph	1	0	CH(CH ₂ OH) ₂	3	H	27
Ph	1	1	CH(OH)CH ₃	3	H	28
Ph	1	2	OCH ₂ CH ₂ OH	3	H	29
Ph	1	0	H	3	H	30
Ph	1	0	H	2	H	3*
Ph	1	0	CH ₃	2	H	31
Ph	1	1	CH ₃	2	H	4*
2-furyl	2	0	H	3	H	32
2-thienyl	1	0	H	3	H	33
Ph	2	0	H	3	CH(CH ₃) ₂	5*
2-thienyl	2	0	H	3	CH(CH ₃) ₂	34
3-thienyl	1	0	H	3	H	35
2-thienyl	1	0	H	2	H	36
3-thienyl	1	0	H	2	H	37
2-furyl	1	0	H	3	H	38
Ph	2	0	H	3	CH ₃	39
Ph	2	0	H	3	CH ₂ CH ₂ CH ₃	40
Ph	1	0	H	3	CH(CH ₃) ₂	41
2-furyl	1	0	H	3	CH(CH ₃) ₂	42
2-thienyl	1	0	H	3	CH(CH ₃) ₂	43
2-furyl	1	0	H	2	H	44
Ph	2	0	H	3	CH ₂ CH ₃	6*
Ph	2	0	H	3	(CH ₂) ₂ CH(CH ₃) ₂	45

Substituent						Denoted
Ar	m	n	R ₂	p	R ₃	
Ph	1	0	H	3	CH ₃	46
Ph	1	0	H	3	CH ₂ CH ₃	47
Ph	1	0	CH ₃	3	H	7*
Ph	1	1	CH ₃	3	H	48
Ph	1	0	CH ₃	3	H	49
Ph	1	0	H	3	CH ₂ CH ₂ CH ₃	50

[0036] The following detailed examples are provided to further illustrate the synthesis:

Compound 1; [Phe²,Hgn⁴,Orn(*i*-Pr)⁸]VT:

[0037] The amino acid derivatives used were Boc-Cys(Trt)-OH, Fmoc-Phe-OH, Fmoc-Ile-OH, Fmoc-Hgn-OH, Fmoc-Asn(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Pro-OH, Fmoc-Orn(Mmt)-OH and Fmoc-Gly-OH. Fmoc-Hgn-OH was synthesised as mentioned above. Analytical HPLC was performed on a Waters 600 Liquid Chromatograph using a Vydac C18, 5 μ 4.6 x 250 mm, column at a flow rate of 2 ml/min. Preparative HPLC was performed on a Waters 2000 Liquid Chromatograph using a Prepak 47 x 300 mm cartridge at a flow rate of 100 ml/min. Final compound analysis was performed on a 1100 Agilent Liquid Chromatograph using a Vydac C18, 5 μ 2.1 x 250 mm, column at a flow rate of 0.3 ml/min. Mass spectra were recorded on a Finnigan MAT spectrometer.

[0038] The fully protected peptide resin was synthesised on an Applied Biosystems 9050 Peptide Synthesiser starting from 2 g (0.5 mmol) of Tentagel-S-RAM resin (Peptides International). DIC/HOBt mediated single couplings with a 4-fold excess of amino acid derivatives were performed. The Fmoc group was removed with 20% piperidine in DMF. Upon completion of the automated synthesis, the resin was transferred into a manual synthesis vessel and was treated with DCM/TIS/TFA 93/5/2 (v/v/v) solution (30 ml) for 2 x 1.5 hours for removal of the Mmt group. The resin was thoroughly washed with DCM and was subsequently suspended in 15 ml of 1,2-dichloroethane/TMOF 1:1 (v/v). 0.2 ml of acetone was then added followed by 0.6 g of NaBH(OAc)₃. The suspension was shaken overnight and the resin was washed with methanol, DMF and DCM and dried in *vacuo*. The resin was then treated with 30 ml of the TFA/TIS/H₂O 96/2/2 (v/v/v) solution for 1.5 hours and filtered off. The filtrate was evaporated and the crude linear peptide was precipitated with diethyl ether. The precipitate was immediately dissolved in 500 ml of 10% TFA (aq), and the peptide was oxidised by adding 0.1 M I₂ in methanol to the magnetically stirred solution until yellow color persisted. Excess of iodine was reduced with ascorbic acid. The reaction mixture was then cooled with crushed ice and pH was adjusted to about 5 by adding concentrated ammonia (aq). The mixture was loaded onto an HPLC column and purified using a triethylammonium phosphate buffer with pH 5.2. The compound was eluted with a gradient of acetonitrile. The fractions with a purity exceeding 97% were pooled, and the resulting solution was diluted with 2 volumes of water. The solution was reloaded onto the column which was then washed with 2 l of 0.1 M ammonium acetate (aq) and equilibrated with 2% acetic acid (aq). The compound was eluted with a fast (3%/min) gradient of acetonitrile. The fractions containing the desired product were pooled and lyophilised. 168 mg (~30% yield) of white amorphous powder was obtained. HPLC: Rt=8.5 min, gradient: 20→40% B over 20 min, t=40°C, solvent A 0.01% TFA (aq), solvent B 70% CH₃CN, 0.01% TFA (aq); Purity: 98.8%; MS (M+H⁺): expected 1048.5, observed 1048.5.

Compound 4; [Phe²,Asn(Et)⁴,Dbu⁸]VT:

[0039] The amino acid derivatives used were Boc-Cys(Mob)-OH, Boc-Phe-OH, Boc-Ile-OH, Boc-Asp(OFm)-OH, Boc-Asn-OH, Boc-Pro-OH, Boc-Dbu(benzyloxycarbonyl)-OH DCHA salt and Boc-Gly-OH, all purchased from Novabiochem and Bachem. HPLC and MS operations were performed as in the synthesis of compound 1.

[0040] The fully protected peptide resin was manually synthesised starting from 0.6 g (0.4 mmol) of 4-methyl-benzhydrylamine resin (Novabiochem). DCC, PyBOP or DIC/HOBt mediated single couplings with 2.5-fold excess of amino acid derivatives were employed. The Boc group was removed with 50% TFA in DCM containing 1% of *m*-cresol. Upon completion of the synthesis, the

9-fluorenylmethyl ester was removed from the β -carboxylic group of aspartic acid by treatment with 30% piperidine in DMF for 2 x 30 min. The resin was washed with 1 M HOBt in DMF solution for 30 min and then twice with DMF only. The free carboxylic group was amidated by overnight treatment with 2 mmol of ethylamine/PyBOP/DIEA in DMF. The finished resin was washed with methanol, DMF and DCM and dried *in vacuo*. The peptide was cleaved from the resin by using 30 ml of anhydrous HF containing 3 ml of anisole at 0°C for 90 minutes. The HF was evaporated off, and the crude linear peptide was washed with diethyl ether. The peptide was immediately dissolved in 200 ml of 25% acetonitrile/10% TFA (aq) and oxidised as described *supra*. The resulting mixture was loaded directly onto an HPLC column and purified using triethylammonium phosphate buffer at pH 2.3. The subsequent purification steps were identical to the procedure for compound 1. 41 mg (~10% yield) of white amorphous powder was obtained. HPLC: Rt=10.0 min, gradient: 20→40% B over 20 min, t=40°C, solvent A 0.01% TFA (aq), solvent B 70% CH₃CN, 0.01% TFA (aq); Purity: 100%; MS (M+H⁺) : expected 992.5, observed 992.2.

[0041] The other compounds were prepared by analogous variation of these synthetic procedures.


Experimental (biological testing)

***In vitro* receptor assays:**


[0042] Agonist activity of compounds on the hV1a receptor was determined in a transcriptional reporter assay by transiently transfecting a hV1a receptor expression DNA into HEK-293 cells in concert with a reporter DNA containing intracellular calcium responsive promoter elements regulating expression of firefly luciferase. See Boss, V., Talpade, D.J., Murphy, T.J. J. Biol. Chem. 1996, May 3; 271(18), 10429-10432 for further guidance on this assay. Cells were exposed to serial dilutions of compounds diluted 10-fold per dose for 5 hours, followed by lysis of cells, determination of luciferase activity, and determination of compound efficacies and EC₅₀ values through non-linear regression. Arginine-vasopressin (AVP) was used as an internal control in each experiment, and compounds were tested in at least three independent experiments. To determine selectivity, compounds were tested in luciferase-based transcriptional reporter assays expressing the human oxytocin (hOT) receptor. Assays for other receptors (hV2, hV1b, rat V1a and rat V2) were also conducted.

[0043] For further comparative purposes, other reference compounds used were [Phe₂,Orn₈]OT, terlipressin and F180.

[0044] The structure of [Phe₂,Orn₈]OT is:



[0045] The structure of F180 is:



[0046] The results of the *in vitro* assays are depicted in table 2 *infra*. The EC₅₀ value given is the geometric mean expressed in nanomol/L (nM). Selectivity values are given as EC₅₀ ratios.

***In vivo* pharmacological tests:**

[0047] The compounds were tested *in vivo* for duration of action related to a standard dose of AVP. Blood pressure tests were carried out on anaesthetised Sprague-Dawley male rats (weighing 270-300 g) with catheterised jugular vein and carotid artery. The catheterised carotid artery was used to continuously monitor blood pressure and the jugular vein was used for administration of the compounds tested. Rats received intravenous injections of dibenamine prior to dosing to enhance their responsiveness to V1a receptor agonists (*cf.* Dekanski, J., Br. J. Pharmacol. 1952, 7, 567-572). The dosing procedure consisted of one intravenous injection of physiological saline followed by two consecutive injections of a standard dose of AVP (0.1 nmol/kg, \approx ED₇₀), and three to five increasing doses of a given compound selected to give at least a response comparable to the standard dose of AVP. Dosing intervals were set as time for the blood pressure to decrease to a stable baseline.

[0048] Determination of duration of action was based on the decay rate of diastolic arterial blood pressure transient increase.

Specifically, for an exponential decay of plasma concentration, it can be shown that, if the response is measured beyond the distribution phase, the rate of decay near the EC₅₀ is linear and inversely proportional to the elimination half-life (Rowland, M. and Tozer, T. in "Clinical Pharmacokinetics, Concepts and Applications", 3rd ed., Lippincott Williams & Wilkins, Philadelphia, 1995).

[0049] To measure the response decay rate for a given compound, a dose was selected that gave an amplitude of response as similar as possible to the amplitude of response to the second injection of the standard dose of AVP. To normalise for inter-individual variation in V1a-responsiveness, the duration of action was expressed as the ratio of decay rate for this reference AVP response to the decay rate for the equieffective dose of compound for each rat tested. The results obtained for the compounds tested are set forth in table 2.

Table 2. Results of biological testing

Compound tested	EC ₅₀ hV1a receptor (nM)	<i>in vivo</i> duration relative to AVP	selectivity hOT/hV1a
8	0.50	-	11
9	0.68	1.5	+
10	1.15	2.3	11
11	2.96	1.9	+
12	24.96	-	+
13	18.77	-	+
14	0.54	-	75
15	0.61	2.2	43
16	11.88	-	+
17	30.29	-	+
18	29.85	-	+
19	5.99	1.6	+
20	39.28	-	+
21	20.66	-	+
1*	2.02	1.7	+
22	18.13	-	+
23	7.97	-	+
24	4.09	-	+
25	1.40	2.0	23
2*	1.18	1.7	+
26	2.24	2.0	28
27	16.21	-	+
28	5.17	-	+
29	4.77	-	+
30	1.45	1.7	+
3*	1.47	1.7	+
31	3.91	-	+
4*	2.36	1.8	+
32	2.64	2.1	35
33	14.61	-	+
5*	0.25	1.9	117
34	0.73	2.0	72
35	7.30	-	+
36	11.54	-	+
37	7.45	-	+

Compound tested	EC ₅₀ hV1a receptor (nM)	<i>in vivo</i> duration relative to AVP	selectivity hOT/hV1a
38	10.11	-	+
39	0.21	1.9	178
40	0.27	2.0	88
41	0.98	2.6	53
42	6.25	-	+
43	13.71	-	+
44	14.48	-	+
6*	0.29	1.9	86
45	1.65	-	18
46	2.41	2.1	+
47	0.99	1.6	+
7*	2.84	-	+
48	5.70	-	+
49	3.58	-	+
50	1.52	2.4	43
[Phe ² ,Orn ⁸]OT	0.15	1.9	60
terlipressin	82.08	9.1	+
AVP	0.21	0.9	108
F180	0.56	3.8	+

- = not tested
+ = selective hV1a receptor agonist; EC₅₀ hOT/hV1a ratio not determined due to very low agonist efficacy (<30% compared to AVP) at the hOT receptor

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US5459236A \[0005\]](#)
- [US3352843A \[0006\]](#)
- [US2004229798A \[0010\]](#)




Non-patent literature cited in the description

- O'BRIAN et al. Lancet, 2002, vol. 359, 93131209-10 [0002]
- BRUHA, R. et al. Hepatogastroenterology, 2002, vol. 49, 1161-1166 [0010]
- LANDRY, D.W. et al. Circulation, 1997, vol. 95, 1122-1125 [0010]
- ARGENZIANO, M. et al. Circulation, 1997, vol. 96, II-286-II-290 [0010]
- WENZEL, V. et al. N. Engl. J. Med., 2004, vol. 350, 105-113 [0010]




- OKIN, C.R. et al. *Obstet. Gynecol.*, 2001, vol. 97, 867-872 [0010]
- GOLD, J. et al. *Am. J. Cardiol.*, 2000, vol. 85, 506-508 [0010]
- SHARMA, R.M. SETLUR, R. *Anest. Analg.*, 2005, vol. 101, 833-834 [0010]
- SOLANIK, P. et al. *J. Gastroenterol. Hepatol.*, 2000, vol. 18, 152-156 [0010]
- YOSHIOKA, T. et al. *Neurosurgery*, 1986, vol. 18, 565-567 [0010]
- KILL, C. et al. *Int. Arch. Allergy Immunol.*, 2004, vol. 134, 260-261 [0010]
- WESTPHAL, M. et al. *Annual Congress of the Society of Critical Care Medicine*, 2006, [0010]
- LANDRY, D.W. OLIVER, J.A. N. *Engl. J. Med.*, 2001, vol. 345, 8588-8595 [0010]
- BALUNA, R. VITETTA, E.S. *Immunopharm.*, 1997, vol. 37, 117-132 [0010]
- DELBAERE, A. et al. *Endocrine.*, 2005, vol. 26, 285-290 [0010]
- AGARWAL, R. *Cardiol. Clin.*, 2005, vol. 23, 237-248 [0010]
- DEMLING, R.H.J. BURN *Care Rehabil.*, 2005, vol. 26, 207-227 [0010]
- BONDER, C.S. KUBES, P. *Am. J. Physiol.*, 2003, vol. 284, 729-733 [0010]
- SEAL, J.B. GEWERTZ, B.L. *Ann. Vasc. Surg.*, 2005, vol. 19, 572-584 [0010]
- ZOBAN, P. CERNY, M. *Physiol. Res.*, 2003, vol. 52, 507-516 [0010]
- BERMEJO, J.F. MUNOZ-FERNANDEZ, M.A. *Viral Immunol.*, 2004, vol. 17, 535-544 [0010]
- ARROYO, V. ANN. *Hepatol.*, 2002, vol. 1, 72-79 [0010]
- HAINSWORTH, R. *Clin. Auton. Res.*, 2004, vol. 1, 18-24 [0010]
- CHUANG, Y.Y. et al. *Paediatr. Drugs.*, 2005, vol. 7, 11-25 [0010]
- CAU, C. *Minerva Med.*, 1999, vol. 90, 391-396 [0010]
- Handbook of Pharmaceutical Excipients American Pharmaceutical Association, USA and Pharmaceutical Press 2000 0000 [0023]
- WISNIEWSKI, K. KOLODZIEJCZYK, A.S. *Org. Prep. Proced. Int.*, 1997, vol. 29, 338-341 [0028]
- KATES, S.A. ALBERICIO, F. *Solid Phase Synthesis. A Practical Guide* Marcel Dekker 2000 0000 [0029]
- STEWART, J.M. YOUNG, J.D. *Solid Phase Synthesis*, Pierce Chemical Company, 1984, [0029]
- BISELLO et al. *J. Biol. Chem.*, 1998, vol. 273, 22498-22505 [0029]
- MERRIFIELD J. *Am. Chem. Soc.*, 1963, vol. 85, 2149-2154 [0029]
- BARLOS, K. et al. *Peptides* ESCOM Science Publishers B.V. 1992 0000 283-284 [0032]
- FUKUYAMA, T. JOW, C.-K. CHEUNG, M. *Tetrahedron Lett.*, 1995, vol. 36, 6373-6374 [0033]
- BOSS, V. TALPADE, D.J. MURPHY, T.J.J. *Biol. Chem.*, 1996, vol. 271, 1810429-10432 [0042]
- DEKANSKI, J. *Br. J. Pharmacol.*, 1952, vol. 7, 567-572 [0047]
- ROWLAND, M. TOZER, T. *Clinical Pharmacokinetics, Concepts and Applications* Lippincott Williams & Wilkins 1995 0000 [0048]

P A T E N T K R A V


1. Forbindelse valgt blandt en gruppe bestående af:



5



og



10

til anvendelse i behandling af hypertensiv gastropati-blødning, sepsis, svær sepsis, septisk chok, længerevarende og svær hypotension, intradialytisk hypotension, hjertestop, traume-betinget blodtab, vasodilatorisk chok induceret af kardio-pulmonal bypass, milrino-

15 ne-induceret vasodilatorisk chok i kongestivt hjertesvigt, hepatorenalt syndrom type I, anafylaktisk chok, kardiovaskulær ustabilitet induceret af hjernedød,

til anvendelse i behandling af hypotension i svær sepsis, akut respiratorisk distress-

syndrom eller akut lungeskade, eller

til anvendelse i behandling af utilstrækkelig vævsoxygenering, chok induceret af

20 metformin-intoksikation, mitokondrie-sygdom eller cyanidforgiftning, vaskulær lækagesyn-

drom induceret af interleukin-2 eller andre cytokiner, denileukindiftitox eller andre immun-

toksiner eller ovariehyperstimuleringsyndrom, hypertension induceret af nyresygdom i





slutstadium, svære forbrændinger, termisk skade, reperfusionsskade, ascites, vasodepres-

25 sor synkope omfattende vasovagal synkope, postural hypotension med synkope eller neu-



rocardiogenisk synkope, toksisk choksyndrom eller idiopatisk systemisk kapillær lækage-

syndrom (Clarkson's sygdom).


2. Forbindelse valgt blandt en gruppe bestående af:



30



og



- 5 til anvendelse til fremstilling af et lægemiddel til behandling af hypertensiv gastropati- blødning, sepsis, svær sepsis, septisk chok, længerevarende og svær hypotension, intradialytisk hypotension, hjertestop, traumbetinget blodtab, vasodilatorisk chok induceret af kardio-pulmonal bypass, milrinone-induceret vasodilatorisk chok i kongestivt hjertesvigt, hepatorenalt syndrom type I, anafylaktisk chok, kardiovaskulær ustabilitet induceret af
- 10 hjernedød, til anvendelse til fremstilling af et lægemiddel til behandling af hypotension i svær sepsis, akut respiratorisk distress-syndrom eller akut lungeskade eller til anvendelse til fremstilling af et lægemiddel til behandling af utilstrækkelig vævoxygenering, chok induceret af metformin-intoksikation, mitokondrie-sygdom eller cyanidforgiftning, vaskulær lækage-syndrom induceret af interleukin-2 eller andre cytokiner, denileukindiftitox eller
- 15 andre immuntoksiner eller ovariehyperstimuleringsyndrom, hypertension induceret af nyresygdom i slutstadium, svære forbrændinger, termisk skade, reperfusionsskade, ascites, vasodepressor synkope, omfatter vasovagal synkope, postural hypotension med synkope eller neurokardiogen synkope, toksisk choksyndrom eller idiopatisk systemisk kapillær lækagesyndrom (Clarkson's sygdom).